(UVE) Universal Insurance - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US91359V1070
UVE: Homeowners, Renters, Condo, Dwelling, Fire, Liability, Personal Property
Universal Insurance Holdings, Inc. (NYSE: UVE), a leading integrated insurance holding company, specializes in personal residential insurance products, including homeowners, renters, condo unit owners, and dwelling/fire insurance. The company also offers allied lines, other structures coverage, personal property, liability, and personal articles coverages. Operating primarily in the United States, UVE is known for its robust digital strategy, including Clovered.com, a platform that streamlines insurance solutions and claims adjustment through digital applications.
Headquartered in Fort Lauderdale, Florida, UVE was incorporated in 1990 and rebranded from Universal Heights, Inc. in 2001. The companys strategic focus includes actuarial advisory services, reinsurance management, and a multi-channel distribution network comprising independent agents and direct-to-consumer online solutions. This dual approach enhances market reach and customer accessibility.
From a technical standpoint, UVEs stock exhibits stability with an average 20-day volume of 158,716 and a low ATR of 0.57, indicating steady price movements. Trading above its 20, 50, and 200-day SMAs suggests a bullish trend. Fundamentally, with a market cap of $554.13M, a P/E of 7.90, and a robust RoE of 18.22%, UVE demonstrates strong financial health and attractive valuation metrics.
Over the next three months, UVE is expected to leverage its digital innovations and strategic market expansion, particularly in high-risk areas like hurricane-prone regions. The company may enhance its independent agent network and online solutions, potentially increasing market share. The stocks technical strength and fundamental soundness position it for continued growth, supported by a stable uptrend and undervalued P/E ratio.
Additional Sources for UVE Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
UVE Stock Overview
Market Cap in USD | 656m |
Sector | Financial Services |
Industry | Insurance - Property & Casualty |
GiC Sub-Industry | Property & Casualty Insurance |
IPO / Inception | 1992-12-14 |
UVE Stock Ratings
Growth 5y | 44.8% |
Fundamental | 55.5% |
Dividend | 40.0% |
Rel. Strength | 5.3 |
Analysts | 4/5 |
Fair Price Momentum | 22.00 USD |
Fair Price DCF | 104.20 USD |
UVE Dividends
Dividend Yield 12m | 3.05% |
Yield on Cost 5y | 4.47% |
Annual Growth 5y | 0.00% |
Payout Consistency | 76.5% |
UVE Growth Ratios
Growth Correlation 3m | 90.8% |
Growth Correlation 12m | 60.7% |
Growth Correlation 5y | 57.6% |
CAGR 5y | 9.06% |
CAGR/Max DD 5y | 0.17 |
Sharpe Ratio 12m | 1.48 |
Alpha | 15.95 |
Beta | 0.849 |
Volatility | 44.13% |
Current Volume | 161k |
Average Volume 20d | 185.5k |
As of April 11, 2025, the stock is trading at USD 22.10 with a total of 160,976 shares traded.
Over the past week, the price has changed by -7.38%, over one month by +6.10%, over three months by +17.18% and over the past year by +20.07%.
Partly, yes. Based on ValueRay Fundamental Analyses, Universal Insurance (NYSE:UVE) is currently (April 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 55.52 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of UVE as of April 2025 is 22.00. This means that UVE is currently overvalued and has a potential downside of -0.45%.
Universal Insurance has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy UVE.
- Strong Buy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, UVE Universal Insurance will be worth about 24.2 in April 2026. The stock is currently trading at 22.10. This means that the stock has a potential upside of +9.5%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 27 | 22.2% |
Analysts Target Price | 27 | 22.2% |
ValueRay Target Price | 24.2 | 9.5% |